Bellamy’s Australia, the child’s formula maker, announced Wednesday that it won approval to sell certain products in the Chinese stores, thus easing the regulatory obstacle that has been affecting the company for years.
Although not a final or company-wide approval, it suggested that the regulatory limbo that beset and dragged the closely watched Australian exporter on its shares would soon end.
Since 2018, China has declared that its State Market Regulation Administration (SAMR) needs to approve imports after a wave of imports has been triggered by lingering safety concerns about domestic product.
Bellamy’s, based on Tasmania Island, was waiting for the approvals of its ViPlus Dairy Plant in Victoria on several years and on Thursday received three SAMR formulation clearances.
Final clearance was still needed, and the approvals did not cover formula produced in another facility, the company added.
The shares of Bellamy increased almost a quarter in trading in the afternoon and closed 16 %, their biggest gain in 15 months, while Australia increased 1 million in the broader market. The share remains 51 percent below the previous year.
Mathan Somasundaram, a Blue Ocean Equities market portfolio strategist, said: “This is a partial win but this is not yet there.”
Bellamy sees China as its leading growth market, which it uses to re-sell products in its home country for the most of its sales by Chinese customers in Australia.
In February, its half-year profit decreased by almost two thirds, affected by delays in securing Chinese regulatory approvals and declining domestic sales.

